Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
64 participants
INTERVENTIONAL
2008-05-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of T-PRED(TM) Compared to Pred Forte(R) II
NCT00854061
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
NCT01915238
Age-Related Eye Disease Study (AREDS)
NCT00000145
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials
NCT06445322
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
NCT03946085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T-Pred
Tobramycin prednisolone acetate combination
T-PRED
T-PRED sterile ophthalmic solution
Pred Forte
Prednisolone acetate
Pred Forte
Pred Forte sterile ophthalmic solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T-PRED
T-PRED sterile ophthalmic solution
Pred Forte
Pred Forte sterile ophthalmic solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bausch & Lomb Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tim McNamara, PharmD
Role: STUDY_DIRECTOR
ISTA Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ISTA Pharmaceuticals, Inc.
Irvine, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL-PKT-0312081-P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.